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ABSTRACT 
Rivaroxaban is oral anti-coagulant drug, used in the treatment of various blood disorders. A sensitive and accurate liquid 
chromatographic methodfor the quantification of rivaroxaban in human plasma was successfully developed. Protein precipitation 
was used for sample preparation. Quantification of analyte was achieved on phenomenexluna C8 (5µm x 25cm x 4.6mm i.d.) column 
using methanol:water:dimethyl sulfoxide (50:45:5, v/v/v) as mobile phase at a flow rate of 1ml/min. Detection was achieved at 
252nm over the linearity concentration range of 5-40µg/ml. Retention time was found 6.2 min. The LOD and LOQ were found to be 
1.5 µg/ml and 4.5 µg/ml, respectively.The developed method was validate as per US FDA guidelines.  
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INTRODUCTION:  
Anticoagulants are given to prevent the blood clotting or 
to prevent existing clots from getting larger. Clots can 
block the blood flow to the brain or to the heart 
muscle.These blockages may cause a heart attack or a 
stroke.Rivaroxaban (RIV)is potent and effective oral 
anti-coagulant drug, which is widely used in the 
treatment of thromboembolic ailments, myocardial 
infarction, stroke, angina pectoris and various blood 
clotting related disorders. IUPAC name of RIV is (S)-5-
chloro-N-{[2-oxo-3-[4-(3-oxomorpholin-4-yl) phenyl] 
oxazolidin-5-yl]methyl}thiophene-2-carboxamide 
(Fig.1).RIV is a small molecule(molecular weight 436 
gmol
-1
) and almost insoluble in water. It is rapidly 
absorbed through gastro intestinal tract and attains 
maximum plasma concentrations at 2–4 h after oral 
administration. Oral bioavailability of RIV is high (92–
98 %) with the dose of 10 mg,  irrespective of food 
intake. RIV acts as anticoagulant by inhibiting the factor 
Xa.  Inhibiting factor Xa,it activates the generation of 
thrombin molecules.  
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Figure 1: Chemical structure of Rivaroxaban 
The factor Xa inhibition occurs mainly as a result of 
RIV binding with S1 and S4 pockets of the serine 
endopeptidaseenzyme with high selectivity. 
The literature review revealed that there are few 
bioanalytical methods reported for the determination of 
rivaroxaban in human blood plasma
1-5
. There is only one 
HPLC-UV method till date for RIV quantification in 
human plasma
3
. The sample preparation in above 
reported method is very tedious, further above method 
utilized acetonitrile and water as mobile phase in the 
ratio 55:45 % v/v. Method requires quite high 
concentration of acetonitrile. However, present studies 
attempts to develop simplified and eco-friendly sample 
preparation procedure and mobile phase to implement 
greener approach for the quantification of RIV in human 
plasma. 
MATERIAL AND METHODS: 
Materials Rivaroxaban was procured as a gratis sample 
from Mehta API Pvt. Ltd., Mumbai, India. 
Chloramphenicol was procured from Panchsheel 
organics, Indore, India. HPLC grade water was procured 
from Medicaps Pvt. Ltd. Dhar, India. Methanol, 
acetonitrile and dimethyl sulfoxide (DMSO) were 
purchased from spectrochem Pvt. Ltd, Mumbai, India. 
Human plasma wascollected from Greater Kailash 
Hospital, Indore, India. The required chromatographic 
solvents and solutions were first filtered through 
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0.45µmmembrane filters (Pall life sciences, India) and 
sonicated prior to use. 
Method Preparation of standard solutions: Stock 
solutions of RIV (1000µg/ml) and Chloramphenicol, 
internal standard (IS) (1000µg/ml) were prepared in 
DMSO. Serial dilutions of stock solutions were prepared 
and used as working standard for analysis.  
Sample preparation: Human plasma (0.1ml) was taken 
in a 2ml poly propylene tube, 20µl of standard drug and 
IS were spiked into it, then 0.5 ml of acetonitrile was 
added. These solutions were vortexed for 1 min and then 
centrifuged for 10 min at 10000 rpm, supernatant was 
injected to chromatographic system. Sample preparation 
was done in triplicate. 
Chromatographic conditions: The mobile phase 
consisted methanol: water: DMSO (50:45:5, % v/v/v) at 
a flow rate of 1.0 ml/min. The required chromatographic 
solvents and solutions were first filtered through 0.45 
µm membrane filters (Pall life sciences, India) and 
sonicated prior to use. Chromatographic separation was 
achieved at ambient temperature on HPLC system 
having a pump (Shimadzu LC 10ATVP) with 20 L 
Rheodyne injector, Phenomenex Luna C8 (5 m x 25cm 
x 4.6mm i.d) column and SPD-10 AVP photodiode array 
(PDA) UV-Visible detector set at 252nm and equipped 
with CLASS-VP software (Shimadzu, Japan). The run 
time was kept 8 min. Calibration curve is in the range of 
5 µg/ml to 40 µg/ml. Peak purity is checked by 
obtaining ratio chromatogram. 
Sample analysis: The responses of sample solutions 
were measured at 252 nm for quantitation of RIV by 
using the HPLC method as described above. The 
amounts of RIV present in sample solution were 
determined by applying value of peak area to the 
regression equation of the calibration graph. Validation 
was done as per US FDA guidelines. The specificity of 
the developed method was determined by comparing test 
results obtained from RIV solution containing plasma 
with that of results obtained from standard RIV solution. 
The linearity equation was obtained by linear regression 
analysis method by plotting a graph between mean peak 
response area and concentration. LOD and LOD were 
determined using dilution method. The recovery 
experiments were performed by the standard addition 
method. 
RESULTS AND DISCUSSION: 
The literature revealed that RIV is insoluble in water and 
less soluble in various solvents. DMSO was used as 
solvent for RIV. Several trials were performed to 
remove the interferences of biological matter in the 
sample. Final sample preparation involves precipitation 
of undesirable matrix component by protein 
precipitation using acetonitrile. 
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Figure 2: RP-HPLC Chromatogram of Rivaroxaban with IS in human plasma 
To optimize the HPLC parameters, several mobile phase 
compositions were tried.  
Table 1: System suitability test for the proposed HPLC 
method 
Parameters Rivaroxaban ± % RSD
a
 
Retention time (Rt), min  6.2 ± 0.03 
Tailing factor 1.16 ± 0.04 
Resolution (Rs) 2.19 ± 0.04 
Theoretical plates (N) 4249 ± 0.8 
a
% Relative standard deviation, (n=6) 
A satisfactory separation of RIV with good peak 
symmetry and steady baseline was obtained with the 
mobile phase methanol: water: DMSO (50:45:5, 
%v/v/v) at a flow rate of 1.0 ml/min. Quantitation was 
achieved with UV detection at 252nm based on peak 
area. Complete resolution of the peak with clear baseline 
separation was obtained (Fig. 2). The system suitability 
test parameters are shown in Table 1. 
Method validation parameters: 
System suitability: System suitability parameters were 
found to be satisfactory. All the parameters, theoretical 
plate count (N) ˃4100, resolution (Rs) ˃2 and tailing 
factor ˃1.2 were within acceptable value. The relative 
standard deviation (RSD) of peak area was found to be 
˂2percentage. 
Specificity: There is no chemical interaction between the 
RIV and IS, and both the RIV and IS was resolved well. 
There were no interfering peak/s found in the 
chromatogram obtained from the blank plasma at the 
retention times of RIV and IS. 
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Linearity: The linear regression correlation coefficient 
of 0.975 was obtained over the six different 
concentration levels ranging from5 µg/ml to 40 µg/ml 
for RIV. The average slope and intercept of linearity 
equations were 26709.03 and -21174.56 respectively. 
Regression analysis data are summarized in Table 2. 
Table 2: Regression analysis of calibration graphs for 
RIV for the proposed HPLC methods 
Parameters HPLC 
Conc. Range 5-40 µg/ml 
Slope 26709.03 
SD of slope 110.98 
Intercept -21174.56 
SD of intercept 1154.79 
correlation 0.9735 
Regression equation y= 26709x-21174 
Y = peak area 
x = Concentration of analyte in µg/ml 
Limit of detection (LOD) and limit of quantitation 
(LOQ): The concentration of RIV for determination of 
LOD was 1.5 µg/ml, which indicates the sensitivity of 
the method. Similarly, LOQ was found 4.5 µg/ml, which 
proves that RIV can be estimated at low concentration. 
Accuracy and Precision: The interday and intraday 
precision values of RIV for various concentrations 
ranged from 0.57% to 1.15% RSD and0.46% to 0.88% 
RSD, respectively. The values for accuracy were also 
found within acceptable limits at the same 
concentrations. The data are presented in Table 3. 
 
Table 3:  Method validation parameters for estimation 
of Rivaroxaban 
Parameters HPLC 
Limit of detection 1.5 µg/ml 
Limit of quantification 4.5 µg/ml 
Recovery 99.38-100.44% 
Repeatability (%RSD, 
n=6) 
0.64 
Intermediate Precision  
Interday (%RSD, n=3) 0.57-1.15 
Intraday (%RSD, n=3) 0.46-0.88 
Robustness (%RSD) < 2% 
a%RSD = Relative standard deviation 
Robustness: The developed method was found to be 
robust during robustness studies, the %RSD was found 
to be ˂2 in each case. The low values of %RSD showed 
the robustness of the method (Table 3). 
Sample and standard stability: The stability of RIV 
sample in human plasma and the standard solutions 
were determined. Peak area and retention time variation 
were found to be <1%. Also, no significant change in 
peak area was observed during 24 h. 
CONCLUSIONS: 
In the present study, an attempt was made to develop a 
simple, precise, selective and sensitive validated 
bioanalytical method of RIV using RP-HPLC. This 
method is quite simple, economic, less time-consuming 
method up to date for the determination of RIV in 
plasma with RP-HPLC.  
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